研究表明,尽管一线化疗联合抗血管生成治疗在KRASm NSCLC患者中的疗效仍低于KRASwt患者,但确实改善了KRAS突变患者的生存期。Ghimessy等的研究发现,接受化疗联合贝伐珠单抗治疗的KRASm晚期肺腺癌患者,其OS和PFS均显著低于KRASwt患者(OS:14.23个月 vs. 21.57个...
e, Live cell target engagement is observed at WT KRAS with BI-2852, but not with AMG510 (1). BRET is normalized relative to a saturating (20 µM) dose of BI-2852, as marked. RLU stands for relative luminescence units. Source data Full size image To determine whether the RAS BRET...
specificity of the GpRs and exclude “off-targets” effects, we deleted the region inKIMAT1necessary for the GpRs binding (Supplementary Fig.5d). While, cells transfected with a plasmid harboringKIMAT1WT showed reduced 3D cell invasion and colony formation upon GpRs transfection, cells overexpressin...
(Wt)cell-lines Caco2 and Colo-320.DLD-1(KRAS),HT-29(BRAF)and Caco2(Wt)cell lines were treated with cytokines(TNF伪50 ng,IL-1尾1 ng and IFN纬50ng)and harvested at different time points(1-24 h).KRAS inhibition was performed by the siRNA-approach.Two colorectal cancer cells DLD-1 ...
*使用本品系发表的文献需注明: LKB1-KO/Kras-G12D-Luc cell line (Cat. NO. NM-YD07) was purchased from Shanghai Model Organisms Center, Inc.. 验证数据 Fig1. The genotype of LKB1-KO/Kras-G12D-Luc cell was identified by PCR WT: wild-type cells; H2O: negative water control; 100bp DNA...
Fig1. The genotype of LKB1-KO/Kras-G12D-Luc cell was identified by PCR WT: wild-type cells; H2O: negative water control; 100bp DNA marker from Transgen(BM311) Fig2. Tumor growth curve in LKB1-KO/Kras-G12D-Luc subcutaneously transplanted tumor model (n=6) Fig3. Body weight chan...
I-138 诱导 MDA-MB-436 细胞中 FANCD2 和 PCNA 的单泛素化,增加 HAP-1 USP1 WT 细胞中的 PCNA 和 FANCD2 单泛素化。 MC-GGFG-AM-(10Me-11F-Camptothecin) ZW251 的 Linker-Payload,ZW251 是一种靶向人 GPC3 的抗体-药物偶联物 (ADC)。
These noncovalent GDP pan-KRAS inhibitors exhibit activity against a range of KRAS mutants, as well as against KRAS WT [71,72]. Since these inhibitors selectively recognize the OFF-state of KRAS, their broad activities suggest that most KRAS mutants, such as G12C, dynamically cycle between ...
Furthermore, the combination of KRAS (G12C) inhibitor and WT RAS upstream activators, such as SHP2, is synergistic [105, 106]. SHP2 inhibitors can restore the sensitivity of KRAS-mutant NSCLC to MEK inhibition and increase inactive GDP-bound KRAS. A triplet combination of KRAS (G12C), ...
TargetCell LineKRAS Mutation Status MEK1/2 PANC-1 G12D ASPC-1 G12D Mia-Pa-Ca-2 G12C NCI-H358 G12C SW-620 G12V BxPC-3 WT HT-29 WT All of these cell lines are also established in the 3D spheroid assay. To enquire about additional cell lines or request more information: Contact...